Hera Biolabs
Hera Biolabs, Inc., is an innovative pre-clinical CRO utilising cutting edge gene editing technologies to create novel in vivo models for oncology. Given our mission to accelerate cancer research and drug development, we focus upon rat models to deliver translationally relevant, high-quality results using proprietary technologies. Our first SRG model is the OncoRat®, which is uniquely suited for xenograft studies given its excellent tumour take-rates and ability to deliver masses 10x that of mouse models in half the time – all without the increased risk of genetic drift from multiple passages as observed in mice.